COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Repetitive Transcranial Magnetic Stimulation (rTMS) in Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00920322
Recruitment Status : Terminated (Technical issues impeded recruitment.)
First Posted : June 15, 2009
Last Update Posted : July 21, 2011
Information provided by:
Northside Clinic, Australia

Brief Summary:
This study will report on the outcomes of rTMS administered 3 times per week, compared with the standard protocol of 5 times per week. Participants will be randomly assigned to frequency condition and depressive symptomatology will be measured weekly using a range of clinician and self-rated questionnaires. Participants will remain in the study for at least 4 weeks, with the option of continuing for a further 2 weeks as judged by the study psychiatrist. It is hypothesised that rTMS administered three times per week will be equally as effective as rTMS administered five times per week in reducing depressive symptomatology.

Condition or disease Intervention/treatment Phase
Depression Device: rTMS 5 x weekly Device: rTMS 3 times weekly Phase 4

Detailed Description:
Numerous studies have demonstrated the efficacy of active rTMS over sham rTMS for depression; however, few have systematically studied the optimal frequency of treatment sessions to achieve this efficacy. To date, the majority of studies have administered rTMS every weekday, although this approach has not been widely contested. In addition, most studies have only assessed the effectiveness of rTMS over a two week period, which has resulted in some improvement in depressive symptomatology; however, a longer treatment course would likely result in greater improvement. In this study depressed patients will be randomly assigned to receive rTMS either 3 or 5 times per week, for a period of 4-6 weeks. A range of rating scales will be used to assess the improvement of depressive symptomatology within and between the two frequency groups, to ultimately determine whether TMS is needed 5 times per week to achieve adequate anti-depressant effects or whether 3 times per week is sufficient in achieving a similar level of efficacy for patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised Study of rTMS in Depression
Study Start Date : May 2009
Estimated Primary Completion Date : August 2011
Estimated Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: five times weekly
Patients will receive rTMS on each weekday for 4 weeks (5 x weekly)
Device: rTMS 5 x weekly
Patients will receive rTMS five times weekly for 4 weeks

Experimental: three times weekly
Patients will receive rTMS three times weekly for four weeks
Device: rTMS 3 times weekly
Patients will receive rTMS 3 times weekly for 4 weeks

Primary Outcome Measures :
  1. Depression Rating Scales [ Time Frame: weekly ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged >/= 18
  • DSM-IV diagnosis of Major Depressive Episode (bipolar or MDD)
  • MADRS score >/= 20
  • Able to give informed consent
  • Psychoactive medication dosages have been stable for a period of 4 weeks prior to entry in the study

Exclusion Criteria:

  • Co-morbid alcohol or drug abuse or dependence (last 3 months), current eating disorder, mental retardation, schizophrenia, rapid cycling bipolar
  • A history of mood 'switching' in response to other treatments, which cannot be contained by concurrent treatment, e.g., mood stabiliser
  • Pregnancy
  • Significant neurological disorder that increases seizure risk
  • Metal objects in the head, pacemakers, or a history of epilepsy
  • Patients who have failed to respond to a course of ECT in their current episode of depression
  • A high risk of suicide

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00920322

Layout table for location information
Australia, New South Wales
Northside Clinic
Greenwich, New South Wales, Australia, 2065
Sponsors and Collaborators
Northside Clinic, Australia
Layout table for investigator information
Principal Investigator: Colleen Loo, MBBS, FRANZCP, MD University of NSW
Layout table for additonal information
Responsible Party: Associate Professor Colleen Loo, University of NSW Identifier: NCT00920322    
Other Study ID Numbers: NSG HREC 153
First Posted: June 15, 2009    Key Record Dates
Last Update Posted: July 21, 2011
Last Verified: July 2011
Keywords provided by Northside Clinic, Australia:
Transcranial Magnetic Stimulation
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders